Drug Profile
Rilematovir - Janssen Sciences Ireland UC
Alternative Names: JNJ-53718678; JNJ-678; JNJ-8678Latest Information Update: 23 May 2022
Price :
$50
*
At a glance
- Originator Janssen Sciences Ireland UC
- Developer Janssen Research & Development; Janssen Sciences Ireland UC
- Class Antivirals; Halogenated hydrocarbons; Imidazoles; Indoles; Pyridines; Small molecules; Sulfones
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Respiratory syncytial virus infections
Most Recent Events
- 23 May 2022 Janssen Sciences Ireland completes pre-approval access programme for Respiratory Syncytial Virus (In Adults, In Children, In the elderly) in Hungary, Italy, Spain, Sweden, and the United Kingdom (PO) in May 2022 (NCT04221412)
- 28 Apr 2022 Janssen Research and Development terminates a phase IIb PRIMROSE trial in Respiratory syncytial virus infections (In adults, In the elderly) in Argentina, Bulgaria, Canada, Germany, Hungary, Italy, Japan,Poland, South Africa, Spain, Sweden, Thailand, Ukraine and in the US, due strategic decision (NCT04978337).
- 27 Apr 2022 Janssen Research & Development terminates a phase III clinical trials in Respiratory syncytial virus infections (In children, In infants, In neonates) in Poland, Belgium, Czech Republic, Hungary, Sweden, Germany, Spain (PO) (NCT04583280) (EudraCT2020-002023-11)